Potently neutralizing and protective human antibodies against SARS-CoV-2

Seth J. Zost, Pavlo Gilchuk, James Brett Case, +38

Nature

Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition

Allison J. Greaney, Tyler N. Starr, Pavlo Gilchuk, +17

Cell Host & Microbe

Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies

Rita E. Chen, Xianwen Zhang, James Brett Case, +29

Nature Medicine

Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein

Seth J. Zost, Pavlo Gilchuk, Rita E. Chen, +28

Nature Medicine

Diverse PanelViral DiagnosticsVaccine TargetViral PathogenesisImmunology +8

Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein

Naveenchandra Suryadevara, Swathi Shrihari, Pavlo Gilchuk, +16

Cell

Vaccine TargetN-terminal DomainViral PathogenesisImmunologySars-cov-2 Spike Protein +6

Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection

Emma S. Winkler, Pavlo Gilchuk, Jinsheng Yu, +17

Cell

VaccinationVaccine TargetImmunologyHumoral ImmunityAntibody Engineering +6

High frequency of shared clonotypes in human B cell receptor repertoires

Cinque Soto, Robin Bombardi, Andre Branchizio, +7

Nature

Signal TransductionImmunologyReceptor (Biochemistry)ImmunodominanceAutoimmunity +4

Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktail

Jinhui Dong, Seth J. Zost, Allison J. Greaney, +29

Nature Microbiology

In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains

Rita E. Chen, Emma S. Winkler, James Brett Case, +31

Nature

Sars-cov-2 Variant StrainsVaccine TargetImmunologyMedicineCovid-19

Cross-Neutralizing and Protective Human Antibody Specificities to Poxvirus Infections

Iuliia M. Gilchuk, Pavlo Gilchuk, Gopal Sapparapu, +21

Cell

VaccinationVaccine TargetImmunologyVirologyAntibody Engineering +4